

![]() |
Treatment of diabetic macular edema with sustained-release glucocorticoids: intravitreal triamcinolone acetonide, dexamethasone implant, and fluocinolone acetonide implant |
|
Authors | ||
Published in | Expert Opinion on Pharmacotherapy. 2014, vol. 15, no. 7, p. 953-9 | |
Abstract | Diabetic macular edema (DME) can be treated with intravitreal glucocorticoids, particularly triamcinolone acetonide, dexamethasone (DEX), and fluocinolone acetonide (FA). | |
Keywords | Animals — Delayed-Action Preparations/chemistry — Dexamethasone/administration & dosage/therapeutic use — Diabetic Retinopathy/complications/drug therapy — Drug Implants/administration & dosage/therapeutic use — Fluocinolone Acetonide/administration & dosage/therapeutic use — Glucocorticoids/administration & dosage/therapeutic use — Humans — Intravitreal Injections — Macular Edema/complications/drug therapy — Triamcinolone Acetonide/administration & dosage/therapeutic use | |
Identifiers | PMID: 24661081 | |
Full text | ||
Structures | ||
Research group | Ophtalmologie expérimentale (925) | |
Citation (ISO format) | CIULLA, Thomas A et al. Treatment of diabetic macular edema with sustained-release glucocorticoids: intravitreal triamcinolone acetonide, dexamethasone implant, and fluocinolone acetonide implant. In: Expert Opinion on Pharmacotherapy, 2014, vol. 15, n° 7, p. 953-9. https://archive-ouverte.unige.ch/unige:90428 |